Three studies should shift thinking about the causes of inflammatory bowel disease. It seems that researchers have been focusing on the wrong cytokine as a driving force.
This is a preview of subscription content, log in via an institution to check access.
Katie Ris
References
Duerr R.H. et al. Science 314, 1461–1463 (2006).
Hue, S. et al. J. Exp. Med. 203, 2473–2483 (2006).
Kullberg, M.C. et al. J. Exp. Med. 203, 2485–2494 (2006).
Oppmann, B. et al. Immunity 13, 715–725 (2000).
Becker, C. et al. J. Clin. Invest. 112, 693–706 (2003).
Neurath, M.F., Fuss, I., Kelsall, B.L., Stuber, E. & Strober, W. J. Exp. Med. 182, 1281–1290 (1995).
Simpson, S.J. et al. J. Exp. Med. 187, 1225–1234 (1998).
Ivanov, I.I. et al. Cell 126, 1121–1133 (2006).
Uhlig, H.H. et al. Immunity 25, 309–318 (2006).
Yen, D. et al. J. Clin. Invest. 116, 1310–1316 (2006).
Mannon, P.J. et al. N. Engl. J. Med. 351, 2069–2079 (2004).
Becker, C. et al. J. Immunol. 177, 2760–2764 (2006).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Neurath, M. IL-23: a master regulator in Crohn disease. Nat Med 13, 26–27 (2007). https://doi.org/10.1038/nm0107-26
Issue Date:
DOI: https://doi.org/10.1038/nm0107-26
- Springer Nature America, Inc.
This article is cited by
-
Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn’s Disease
Digestive Diseases and Sciences (2023)
-
Modulation of macrophage inflammatory function through selective inhibition of the epigenetic reader protein SP140
BMC Biology (2022)
-
Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn’s Disease
Digestive Diseases and Sciences (2020)
-
T lymphocytes in the intestinal mucosa: defense and tolerance
Cellular & Molecular Immunology (2019)
-
Macrophages in intestinal inflammation and resolution: a potential therapeutic target in IBD
Nature Reviews Gastroenterology & Hepatology (2019)